Glaukos (NYSE:GKOS) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Glaukos (NYSE:GKOS) had its price objective upped by analysts at Wells Fargo & Company from $135.00 to $138.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has an “overweight” rating on the medical instruments supplier’s stock. Wells Fargo & Company‘s price target suggests a potential downside of 1.70% from the company’s previous close.

Several other brokerages also recently weighed in on GKOS. BTIG Research boosted their price objective on Glaukos from $131.00 to $141.00 and gave the company a “buy” rating in a research report on Thursday. Piper Sandler reiterated an “overweight” rating and set a $165.00 price target on shares of Glaukos in a report on Wednesday, January 14th. Stifel Nicolaus increased their price target on shares of Glaukos from $115.00 to $160.00 and gave the company a “buy” rating in a research report on Thursday, January 22nd. Needham & Company LLC raised their price target on shares of Glaukos from $127.00 to $136.00 and gave the stock a “buy” rating in a report on Thursday. Finally, The Goldman Sachs Group restated a “buy” rating and issued a $138.00 price objective on shares of Glaukos in a research report on Friday, January 9th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $138.85.

Glaukos Stock Down 2.3%

Shares of NYSE:GKOS opened at $140.38 on Thursday. The stock’s 50-day moving average price is $114.02 and its 200-day moving average price is $107.68. Glaukos has a 12-month low of $73.16 and a 12-month high of $146.75. The stock has a market capitalization of $8.22 billion, a P/E ratio of -42.80 and a beta of 0.94. The company has a current ratio of 5.43, a quick ratio of 4.06 and a debt-to-equity ratio of 0.10.

Glaukos (NYSE:GKOS) last released its earnings results on Wednesday, April 29th. The medical instruments supplier reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.12. Glaukos had a negative return on equity of 6.92% and a negative net margin of 34.34%.The company had revenue of $150.57 million during the quarter, compared to analyst estimates of $137.00 million. During the same quarter in the previous year, the company posted ($0.22) EPS. Glaukos’s revenue for the quarter was up 41.2% on a year-over-year basis. On average, equities analysts anticipate that Glaukos will post -0.57 earnings per share for the current year.

Insider Activity

In related news, Director Aimee S. Weisner sold 15,000 shares of the business’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $117.38, for a total transaction of $1,760,700.00. Following the transaction, the director owned 18,806 shares in the company, valued at $2,207,448.28. The trade was a 44.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Alex R. Thurman sold 2,511 shares of the stock in a transaction dated Wednesday, March 25th. The stock was sold at an average price of $106.46, for a total transaction of $267,321.06. Following the completion of the transaction, the chief financial officer directly owned 41,967 shares of the company’s stock, valued at approximately $4,467,806.82. The trade was a 5.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 19,657 shares of company stock valued at $2,250,060. Corporate insiders own 5.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in GKOS. Janus Henderson Group PLC lifted its stake in shares of Glaukos by 183.4% in the 4th quarter. Janus Henderson Group PLC now owns 3,018,787 shares of the medical instruments supplier’s stock valued at $340,855,000 after purchasing an additional 1,953,578 shares during the period. Primecap Management Co. CA grew its stake in Glaukos by 49.8% in the fourth quarter. Primecap Management Co. CA now owns 3,376,928 shares of the medical instruments supplier’s stock worth $381,289,000 after purchasing an additional 1,123,140 shares during the period. Goldman Sachs Group Inc. raised its holdings in Glaukos by 209.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,350,425 shares of the medical instruments supplier’s stock worth $152,476,000 after purchasing an additional 913,458 shares in the last quarter. Millennium Management LLC raised its holdings in Glaukos by 75.3% in the fourth quarter. Millennium Management LLC now owns 1,609,699 shares of the medical instruments supplier’s stock worth $181,751,000 after purchasing an additional 691,289 shares in the last quarter. Finally, UBS Group AG lifted its position in Glaukos by 316.0% during the fourth quarter. UBS Group AG now owns 873,942 shares of the medical instruments supplier’s stock valued at $98,677,000 after buying an additional 663,849 shares during the period. Institutional investors own 99.04% of the company’s stock.

Glaukos News Summary

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Q1 results and outlook: Glaukos reported a Q1 revenue beat, 41% year-over-year growth, narrower loss and a raised 2026 revenue outlook — the key fundamental catalyst supporting the stock. Zacks: Q1 Earnings Beat & Raised Outlook
• Positive Sentiment: Analyst upgrades: Multiple firms raised ratings/targets after the quarter — BTIG bumped its target to $141 (buy), Wells Fargo to $138 (overweight), JPMorgan to $140 (overweight) and Needham raised its target — these actions validate the quarter’s strength and support further investor interest. BTIG Research PT Raise
• Neutral Sentiment: Analyst target mix: although several firms raised targets and ratings, many new targets are close to the current price, implying limited near-term upside from those specific forecasts. Wells Fargo PT Raise
• Neutral Sentiment: Market reaction nuance: after the after-hours jump, some intraday profit-taking is common when a stock has run up; elevated volume today suggests active repositioning by traders. OCBJ: After-Hours Move
• Negative Sentiment: Some revised price targets are below the current market price (e.g., Needham and others), which can encourage short-term selling or cap upside until guidance and execution confirm sustained growth. Needham PT Update

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.